Table 2.
Types of insulin therapy according to geographic region
| |
Insulin Monotherapy * |
|
|
|
|---|---|---|---|---|
| Type of insulin monotherapy | Southeast | South | Northeast/North | Mid-west |
| NPH |
152 (96.8) |
41 (83.7) |
275 (94.5) |
54 (87.1) |
| Glargine or Detemir |
5 (3.2) |
8 (16.3) |
16 (5.5) |
8 (12.9) |
| |
Combined Insulin Therapy** |
|
|
|
|
Type of combination of insulin therapy |
Southeast |
South |
Northeast/North |
Mid-west |
| NPH plus Regular |
573 (46.2) |
357 (46.9) |
677 (82.7) |
79 (47.0) |
| NPH plus Lispro |
271 (21.8) |
194 (25.5) |
12 (1.5) |
11 (6.5) |
| NPH plus Aspart |
91 (7.3) |
38 (5.0) |
13 (1.6) |
4 (2.4) |
| NPH plus Glulisine |
6 (0.5) |
4 (0.5) |
7 (0.9) |
5 (3) |
| Glargine plus regular |
16 (1.3) |
12 (1.6) |
10 (1.2) |
1 (0.6) |
| Glargine plus Lispro |
158 (12.7) |
71 (9.3) |
25 (3.1) |
48 (28.6) |
| Glargine plus Aspart |
57 (4.6) |
67 (8.8) |
32 (3.9) |
6 (3.6) |
| Glargine plus Glulisine |
2 (0.2) |
3 (0.4) |
3 (0.4) |
13 (7.7) |
| Detemir plus regular |
4 (0.3) |
- |
5 (0.6) |
- |
| Detemir plus Lispro |
25 (2) |
3 (0.4) |
9 (1.1) |
1 (0.6) |
| Detemir plus Aspart |
37 (3) |
12 (1.6) |
24 (2.9) |
- |
| Detemir plus Glulisine | 1 (0.1) | - | 2 (0.2) | - |
The data are presented as n (%); * /** p<0.001 for comparisons among the groups.